Form 10-K · Annual report
KLA Corporation 10-K, filed Aug 6, 2026
- Filed
- CIK
- 0000319201
- Accession no.
- 0000319201-26-000027
Summary
KLA Corporation reported higher fiscal 2026 revenue and net income, effected a ten-for-one stock split, and increased its dividend and share repurchase authorization. The company said it expects continued revenue growth in fiscal 2027, citing AI, HPC, leading-edge node and advanced packaging demand.
Key points
- KLA reported fiscal 2026 total revenues of $13.58 billion, up from $12.16 billion in fiscal 2025, and net income of $4.83 billion, up from $4.06 billion.
- KLA effected a ten-for-one stock split on June 11, 2026, and raised its quarterly dividend to $0.230 per share, its 17th consecutive annual increase.
- KLA repurchased $2.29 billion of stock and paid $1.06 billion in dividends in fiscal 2026, with $9.74 billion of repurchase authority remaining as of June 30, 2026.
- Services accounted for about 23% of KLA's total revenues in fiscal 2026, and the company operates three reportable segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB and Component Inspection.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 7.MANAGEMENT’S DISCUSSION EXECUTIVE SUMMARY We are a leading supplier of process control and yield management solutions and services for the semiconductor and related electronics industries. Our broad portfolio of inspection and metrology products, along with related services, software and other offerings, supports R&D and manufacturing of ICs, wafers and reticles. Our products, services and expertise enable our customers to measure, detect, analyze and resolve critical nanometer-scale product defects, helping them to address manufacturing challenges and achieve higher yields at lower cost. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.